Compare ResMed Inc. (RMD) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.28 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 10.2× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| RMD | VEA | |
|---|---|---|
Market Cap | $31.89B | $323.80B |
Volume | 618,314 | 17,001,112 |
Sector | Health | — |
52-Week High | $277.88 | $73.79 |
52-Week Low | $182.82 | $58.90 |
Typical Hold Time | 51 Days | 131 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Vanguard FTSE Developed Markets ETF (VEA) trades at $70.26, down 1.2% today, with a bearish technical signal from moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a recent dividend declared for September 2026. Recent news highlights its cost advantage over peers and mixed institutional activity, with some firms increasing stakes while others reduced positions.
VEA provides diversified international exposure at minimal cost, but near-term technical weakness and reliance on global economic stability pose risks. The fund's appeal lies in its efficiency and yield, yet investors face currency and geopolitical uncertainties inherent in non-U.S. markets. Long-term prospects depend on sustained growth in developed economies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
